Michael Kragh
Impact in
- Oncology top 5%
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
-
- Monoclonal and Polyclonal Antibodies Research
Papers in
- Oncology 32
- HER2/EGFR in Cancer Research 20
- Colorectal Cancer Treatments and Studies 5
-
- Angiogenesis and VEGF in Cancer 6
- Glycosylation and Glycoproteins Research 5
- Co-authors
- Mikkel W. Pedersen (22 shared papers)Ivan D. Horak (25 shared papers)Helle J. Jacobsen (9 shared papers)Klaus Koefoed (9 shared papers)Johan Lantto (18 shared papers)Paul E.G. Kristjansen (8 shared papers)John S. Haurum (2 shared papers)Adam Hey (2 shared papers)
- Journals
- Cancer Research (7 papers)Molecular Cancer Therapeutics (7 papers)Clinical Cancer Research (4 papers)Annals of Oncology (3 papers)Neoplasia (3 papers)
- Partner nations
- United StatesDenmarkSpain
In The Last Decade
Michael Kragh
50 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 84
- Oncology 684
- Radiology, Nuclear Medicine and Imaging 434
- Immunology 295
- Hepatology 73
- Cancer Research 124
Countries citing papers authored by Michael Kragh
This map shows the geographic impact of Michael Kragh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Kragh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Kragh more than expected).
Fields of papers citing papers by Michael Kragh
This network shows the impact of papers produced by Michael Kragh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Kragh. The network helps show where Michael Kragh may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Kragh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 51 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2010 | 174 | |
| 2 | 2008 | 81 | |
| 3 | 2011 | 76 | |
| 4 | 2015 | 72 | |
| 5 | 2019 | 69 | |
| 6 | 2007 | 60 | |
| 7 | 2015 | 58 | |
| 8 | 2013 | 58 | |
| 9 | Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth. | 2005 | 46 |
| 10 | 2017 | 43 | |
| 11 | 2015 | 43 | |
| 12 | 2019 | 42 | |
| 13 | 2017 | 37 | |
| 14 | 2016 | 33 | |
| 15 | 1997 | 33 | |
| 16 | 2005 | 32 | |
| 17 | 2018 | 31 | |
| 18 | 2011 | 30 | |
| 19 | 2003 | 29 | |
| 20 | 2019 | 28 |
About Michael Kragh
Michael Kragh is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Cancer Research, having authored 51 papers that have together received 1.4k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (20 papers), Monoclonal and Polyclonal Antibodies Research (14 papers), Lung Cancer Treatments and Mutations (14 papers), Angiogenesis and VEGF in Cancer (6 papers), Glycosylation and Glycoproteins Research (5 papers), Colorectal Cancer Treatments and Studies (5 papers), Cancer Genomics and Diagnostics (4 papers) and Cancer, Hypoxia, and Metabolism (4 papers). The work is most often cited by research in Oncology (684 citations), Radiology, Nuclear Medicine and Imaging (434 citations), Immunology (295 citations), Hepatology (73 citations) and Cancer Research (124 citations). Michael Kragh has collaborated with scholars based in United States, Denmark and Spain. Frequent co-authors include Mikkel W. Pedersen, Ivan D. Horak, Helle J. Jacobsen, Klaus Koefoed, Johan Lantto, Paul E.G. Kristjansen, John S. Haurum, Adam Hey, Thomas T. Poulsen and Charles Pyke. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Clinical Cancer Research, Annals of Oncology and Neoplasia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.